Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

ABSTRACT: RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

PROVIDER: PRJNA773728 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16532240.fastq.gz	Fastqsanger.gz
	SRR16532241.fastq.gz	Fastqsanger.gz
	SRR16532242.fastq.gz	Fastqsanger.gz
	SRR16532243.fastq.gz	Fastqsanger.gz
	SRR16532244.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Project description:Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation, diminishing adaptive CD8+ T cell antitumor activity. Although innate NK cells are triggered by loss of MHC class I, their response is often inadequate. To increase tumor susceptibility to both innate and adaptive immune elimination, we performed parallel genome-wide CRISPR-Cas9 screens. This identified all components, RNF31, RBCK1, and SHARPIN, of the linear ubiquitination chain assembly complex (LUBAC). Genetic and pharmacologic ablation of RNF31, an E3 ubiquitin ligase, strongly sensitized melanoma, breast and colorectal cancer cells to both NK and CD8+ T cell killing. This occurred in a TNF-dependent manner, causing loss of A20 and non-canonical IKK complexes from TNF Receptor Complex I. Corroborating this preclinically, a small molecule RNF31 inhibitor sensitized human colon carcinoma organoids to TNF and greatly enhanced immune bystander killing of antigen-loss and antigen presentation machinery-deficient tumor cells. These results merit exploration of RNF31 inhibition as a clinical pharmacological opportunity for immunotherapy-refractory cancers.

2022-05-30 | PXD029489 | Pride

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

Project description:Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation, diminishing adaptive CD8+ T cell antitumor activity. Although innate natural killer (NK) cells are triggered by loss of MHC class I, their response is often inadequate. To increase tumor susceptibility to both innate and adaptive immune elimination, we performed parallel genome-wide CRISPR-Cas9 knockout screens under NK and CD8+ T cell pressure. We identify all components, RNF31, RBCK1, and SHARPIN, of the linear ubiquitination chain assembly complex (LUBAC). Genetic and pharmacologic ablation of RNF31, an E3 ubiquitin ligase, strongly sensitizes cancer cells to NK and CD8+ T cell killing. This occurs in a tumor necrosis factor (TNF)-dependent manner, causing loss of A20 and non-canonical IKK complexes from TNF receptor complex I. A small-molecule RNF31 inhibitor sensitizes colon carcinoma organoids to TNF and greatly enhances bystander killing of MHC antigen-deficient tumor cells. These results merit exploration of RNF31 inhibition as a clinical pharmacological opportunity for immunotherapy-refractory cancers.

| S-EPMC9245005 | biostudies-literature

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Project description:We evaluated whether there are transcriptional differences between RNF31-proficient immune-resistant and RNF31-deficient immune-sensitive tumor cells. We stimulated sensitive (sgRNF31- or HOIPIN-8-treated) and resistant (sgCtl, vehicle) BLM tumor cells with TNF for 0 or 6 hours and performed RNA sequencing analysis. Tumor cells sensitized by RNF31 inhibition show a reduced canonical NF-kB and increased pro-death signature upon TNF challenge.

2022-05-14 | GSE186396 | GEO

Innate vs. adaptive lymphocyte gene expression

Project description:Three innate (B1-B, NKT, CD8aaT cells) and adaptive (B2-B, CD4T, CD8abT cells) cell-types were sorted by FACS. Three biological replicates for NKT, CD4T, CD8aaT, CD8abT cells and two biological replicates for B1 and B2 cells were generated and the expression profiles were determined using Affymetrix Mu74Av2 chip. Comparisons between the sample groups allow the identification of genes differentially expressed between the innate and adaptive cell-types. Keywords: cell type comparison, innate vs. adaptive

2006-01-31 | GSE3039 | GEO

ITPK1 sensitizes tumor cells to IgA-dependent neutrophil killing in vivo

Project description:ITPK1 sensitizes tumor cells to IgA-dependent neutrophil killing in vivo

| PRJNA1142465 | ENA

Innate and Adaptive Immunity in Parkinson Disease

Project description:Innate and Adaptive Immunity in Parkinson Disease

| PRJNA646548 | ENA

Innate and Adaptive Immunity in Parkinson Disease

Project description:Innate and Adaptive Immunity in Parkinson Disease

| PRJNA646549 | ENA

ITPK1 sensitizes tumor cells to IgA-dependent neutrophil killing in vivo [CRISPR focused]

Project description:ITPK1 sensitizes tumor cells to IgA-dependent neutrophil killing in vivo [CRISPR focused]